In a pivotal phase III trial, the addition of trastuzumab to chemotherapy in women with HER2 overexpressing metastatic breast cancer was associated to the occurrence of serious AEs, which included cardiac dysfunction, asthenia, leukopenia, dyspnea, and infusion reaction (Leonardi et al., 2010). Here, ERBB2 is linked to asthenia.